METHOTREXATE SODIUM

Search structure
Trade Names:
Synonyms:
Status: Approved (1953)
Entry Type: Small molecule
Molecule Category: Salt
UNII: 3IG1E710ZN
Parent Compound: METHOTREXATE

Structure
InChI Key DASQOOZCTWOQPA-GXKRWWSZSA-L
Smile CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1.[Na+].[Na+]
InChI
InChI=1S/C20H22N8O5.2Na/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;;/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);;/q;2*+1/p-2/t13-;;/m0../s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C20H20N8Na2O5
Molecular Weight 498.41
AlogP 0.27
Hydrogen Bond Acceptor 10.0
Hydrogen Bond Donor 5.0
Number of Rotational Bond 9.0
Polar Surface Area 210.54
Molecular species ACID
Aromatic Rings 3.0
Heavy Atoms 33.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Dihydrofolate reductase inhibitor DailyMed

Metabolites

visNetwork

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 D054198 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
20.56
Musculoskeletal and connective tissue disorders
10.38
Gastrointestinal disorders
7.95
Immune system disorders
6.73
Skin and subcutaneous tissue disorders
6.11
Infections and infestations
6.11
Respiratory, thoracic and mediastinal disorders
5.56
Nervous system disorders
5.34
Injury, poisoning and procedural complications
5.31
Investigations
5.01
Vascular disorders
3.27
Blood and lymphatic system disorders
2.89
Cardiac disorders
2.42
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
2.41

Cross References

Resources Reference
ChEBI 50679
ChEMBL CHEMBL3244648
EPA CompTox DTXSID3037123
FDA SRS 3IG1E710ZN
PubChem 11329481
SureChEMBL SCHEMBL48420
CONTENTS